Literature DB >> 22245095

Overexpression of GRP94 in breast cancer cells resistant to oxidative stress promotes high levels of cancer cell proliferation and migration: implications for tumor recurrence.

Nicolas Dejeans1, Christophe Glorieux, Samuel Guenin, Raphael Beck, Brice Sid, Rejane Rousseau, Bettina Bisig, Philippe Delvenne, Pedro Buc Calderon, Julien Verrax.   

Abstract

Targeting the altered redox status of cancer cells is emerging as an interesting approach to potentiate chemotherapy. However, to maximize the effectiveness of this strategy and define the correct chemotherapeutic associations, it is important to understand the biological consequences of chronically exposing cancer cells to reactive oxygen species (ROS). Using an H(2)O(2)-generating system, we selected a ROS-resistant MCF-7 breast cancer cell line, namely Resox cells. By exploring different survival pathways that are usually induced during oxidative stress, we identified a constitutive overexpression of the endoplasmic reticulum chaperone, GRP94, in these cells, whereas levels of its cytoplasmic homolog HSP90, or GRP78, were not modified. This overexpression was not mediated by constitutive unfolded protein response (UPR) activation. The increase in GRP94 is tightly linked to an increase in cell proliferation and migration capacities, as shown by GRP94-silencing experiments. Interestingly, we also observed that GRP94 silencing inhibits migration and proliferation of the highly aggressive MDA-MB-231 cells. By immunohistochemistry, we showed that GRP94 expression was higher in recurrent human breast cancers than in their paired primary neoplasias. Similar to the situation in the Resox cells, this increase was not associated with an increase in UPR activation in recurrent tumors. In conclusion, this study suggests that GRP94 overexpression may be a hallmark of aggressiveness and recurrence in breast cancers.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245095     DOI: 10.1016/j.freeradbiomed.2011.12.019

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  36 in total

Review 1.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

2.  Development of radamide analogs as Grp94 inhibitors.

Authors:  Aaron Muth; Vincent Crowley; Anuj Khandelwal; Sanket Mishra; Jinbo Zhao; Jessica Hall; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-06-12       Impact factor: 3.641

3.  Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.

Authors:  Yu-Jie Dai; Yi-Bo Qiu; Rong Jiang; Man Xu; Ling-Yao Liao; George G Chen; Zhi-Min Liu
Journal:  Cell Oncol (Dordr)       Date:  2018-01-24       Impact factor: 6.730

4.  Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.

Authors:  Nanette L S Que; Vincent M Crowley; Adam S Duerfeldt; Jinbo Zhao; Caitlin N Kent; Brian S J Blagg; Daniel T Gewirth
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

5.  Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/β-catenin signaling pathway.

Authors:  Tieyi Hu; Niqi Xie; Chuan Qin; Jiasheng Wang; Yi You
Journal:  Tumour Biol       Date:  2015-06-25

6.  Glucose-regulated protein 94 mediates metastasis by CCT8 and the JNK pathway in hepatocellular carcinoma.

Authors:  Po-Li Wei; Chien-Yu Huang; Cheng-Jeng Tai; Uyanga Batzorig; Wan-Li Cheng; Ming-Te Hunag; Yu-Jia Chang
Journal:  Tumour Biol       Date:  2015-12-30

7.  RNAi Screening of the Glucose-Regulated Chaperones in Cancer with Self-Assembled siRNA Nanostructures.

Authors:  Mayurbhai R Patel; Stephen D Kozuch; Christopher N Cultrara; Reeta Yadav; Suiying Huang; Uri Samuni; John Koren; Gabriela Chiosis; David Sabatino
Journal:  Nano Lett       Date:  2016-10-03       Impact factor: 11.189

8.  Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer.

Authors:  Vincent M Crowley; Dustin J E Huard; Raquel L Lieberman; Brian S J Blagg
Journal:  Chemistry       Date:  2017-09-27       Impact factor: 5.236

Review 9.  Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.

Authors:  Yangyang Wang; Xinhui Wang; Cristina R Ferrone; Joseph H Schwab; Soldano Ferrone
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

10.  Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune responses.

Authors:  Maria Kabbage; Mounir Trimeche; Sarra Bergaoui; Philippe Hammann; Lauriane Kuhn; Bechr Hamrita; Hela ben Nasr; Anouar Chaieb; Lotfi Chouchane; Karim Chahed
Journal:  Tumour Biol       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.